Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an update.
Keymed Biosciences Inc. has scheduled a board meeting for March 26, 2026, to review and approve the consolidated annual results for the year ended December 31, 2025. The board will also deliberate on the possible declaration of a final dividend for shareholders, signaling a key governance and capital allocation milestone for the company.
The announcement of the upcoming board meeting outlines an important date for investors monitoring the company’s financial performance and cash distribution policy. Any decision on annual results approval and a potential final dividend could influence market sentiment toward Keymed Biosciences’ profitability, financial health, and commitment to shareholder returns.
The most recent analyst rating on (HK:2162) stock is a Hold with a HK$52.00 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong. The group operates through Keymed Biosciences and its subsidiaries, focusing on developing and commercializing innovative therapies in the biosciences and healthcare sector for domestic and international markets.
Average Trading Volume: 1,461,242
Technical Sentiment Signal: Hold
Current Market Cap: HK$14.77B
For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.